Growth & profitability
- Revenue has grown 65.5% per year over the past 5 years.
INM Financials InMed Pharmaceuticals Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$8M | 34.5% | 0.0% | — | — | $11M |
| 2024 | $5M | -$8M | 23.9% | 0.0% | -$7M | — | $7M |
| 2023 | $4M | -$8M | 33.9% | -192.2% | -$7M | — | $9M |
| 2022 | $1M | -$19M | 49.9% | -1707.3% | -$16M | — | $6M |
| 2021 | — | -$10M | — | — | -$10M | — | $7M |
| 2020 | — | -$9M | — | — | -$7M | — | $6M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$3M | — | — | — | — | $5M |
| Dec '25 | $820188 | -$2M | 22.5% | 0.0% | — | — | $7M |
| Sep '25 | $1M | -$2M | 36.0% | 0.0% | — | — | $9M |
| Jun '25 | $1M | -$2M | 44.2% | 0.0% | — | — | $11M |
| Mar '25 | $1M | -$2M | 13.9% | 0.0% | — | — | $5M |
| Dec '24 | $1M | -$3M | 41.5% | 0.0% | — | — | $3M |
| Sep '24 | $1M | -$2M | 39.0% | 0.0% | — | — | $6M |
| Jun '24 | $1M | -$2M | 36.3% | 0.0% | -$1M | — | $7M |
| Mar '24 | $1M | -$2M | 24.7% | 0.0% | -$2M | — | — |
| Dec '23 | $1M | -$1M | 26.1% | 0.0% | — | — | $10M |
| Sep '23 | $901862 | -$3M | 2.4% | -281.3% | — | — | $7M |
| Jun '23 | $2M | -$338391 | 68.0% | -14.6% | — | — | $9M |
| Mar '23 | $1M | -$2M | 18.6% | -193.2% | — | — | $10M |
| Dec '22 | $469783 | -$2M | 27.9% | -447.2% | — | — | $11M |
| Sep '22 | $320788 | -$4M | -153.1% | -1094.2% | — | — | $9M |
| Jun '22 | $514758 | -$8M | 48.5% | -1528.9% | -$4M | — | $6M |
| Mar '22 | $309585 | -$3M | 58.9% | -1122.7% | -$5M | — | $6M |
| Dec '21 | $265092 | -$4M | 42.1% | -1615.6% | -$3M | — | $11M |
| Sep '21 | — | -$3M | — | — | -$3M | — | $15M |
| Jun '21 | — | -$3M | — | — | — | — | $7M |
Valuation over time
How the market has priced INM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 3.3× (Mar '23) to 1.0× (Jun '26).
P/S
Frequently asked questions
Is INM growing its revenue and profit?
Over the past 5 years, InMed Pharmaceuticals Inc.'s revenue has grown 65.5% per year. These are computed facts, not advice.
How much debt does INM have?
As of FY2025, InMed Pharmaceuticals Inc. reported — of total debt against $11M of cash.
What is INM's profit margin?
In FY2025, gross margin was 34.5%, operating margin —, and net margin -165.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.